|
Garcia-Carmona, J. A.; Vidal-Mena, B.; Conesa-Garcia, E.; Fajardo-Sanchis, J.; Gonzalez-Morales, M.; Ramos-Arenas, V.; Sanchez-Vizcaino-Buendia, C.; Soria-Torrecillas, J.; Perez-Vicente, J.; Garcia-de-Guadiana-Romualdo, L.. N-Terminal-pro-B-type-Natriuretic-Peptide for the diagnosis of cardioembolic ischemic stroke. EUROPEAN JOURNAL OF NEUROLOGY. 2021; 28:571-571.
AÑO: 2021; IF: 6.288
|
|
Garcia-Carmona JA, Simal-Aguado J, Campos-Navarro MP, Valdivia-Munoz F, Galindo-Tovar A. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. Int Clin Psychopharmacol. 2021 Jan;36(1):18-24. doi: 10.1097/YIC.0000000000000339. PubMed PMID: 33086252.
AÑO: 2021; IF: 2.023
|
|
Garcia-Carmona JA, Simal-Aguado J, Campos-Navarro MP, Valdivia-Munoz F, Galindo-Tovar A. Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study. Clin Drug Investig. 2020 May;40(5):459-468. doi: 10.1007/s40261-020-00913-7. PubMed PMID: 32274654.
AÑO: 2020; IF: 2.859
|
|
Martinez-Andres JA, Garcia-Carmona JA. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. Int Clin Psychopharmacol. 2020 May;35(3):163-169. doi: 10.1097/YIC.0000000000000300. PubMed PMID: 31851035.
AÑO: 2020; IF: 1.659
|
|
Martinez-Andres JA, Garcia-Carmona JA. Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. Schizophr Res. 2019 Oct;212:234-236. doi: 10.1016/j.schres.2019.08.001. Epub 2019 Aug 15. No abstract available. PubMed PMID: 31421972.
AÑO: 2019; IF: 3.759
|